Abstract
Bisphosphonate (BP)-induced hepatotoxicity is very rare. There are only a few reports of liver injury after BP treatment, including aledronate and risedronate in postmenopausal osteoporosis patients. We describe hereby the case of a patient with Paget’s disease of bone accompanied by nonalcoholic fatty liver disease (NAFLD) who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. NAFLD had been diagnosed 1 year before presentation, based on liver ultrasonography (US). One day after infusion, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were increased by 8.1, 6.7, and 6.7 times, respectively, compared with pretreatment values. Serum bilirubin remained normal. US revealed hepatic mild homogenous brightness without focal lesion of the liver or biliary ducts. Subsequent biochemical and serologic investigation did not reveal a specific liver or systematic disease. The patient remained asymptomatic, and ALT, AST, and GGT were normalized 7 days post-treatment. Although the mechanism by which ZOL may cause liver damage is elusive, physicians should be aware of this possible adverse effect and ZOL cautiously administered in NAFLD patients.
Similar content being viewed by others
References
Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S (2008) Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club. Osteoporos Int 19:1109–1117
Polyzos SA, Anastasilakis AD, Terpos E (2009) Paget’s disease of bone: emphasis on treatment with zoledronic acid. Exp Rev Endocrinol Metab 4:424–434
Halabe A, Lifschitz BM, Azuri J (2000) Liver damage due to alendronate. N Engl J Med 343:365–366
Carrere C, Duval JL, Godard B, De Jaureguiberry JP, Ciribilli JM (2002) Severe acute hepatitis induced by alendronate. Gastroenterol Clin Biol 26:179–180
Yanik B, Turkay C, Atalar H (2007) Hepatotoxicity induced by alendronate therapy. Osteoporos Int 18:829–831
de La Serna Higuera C, Perez VA, Rodriguez GS, Martinez MJ, Betancourt GA, Martin AM (2001) Alendronate-induced hepatocellular lesion. Gastroenterol Hepatol 24:244–246
Lieverse RJ (1998) Hepatitis after alendronate. Neth J Med 53:271–272
Phillips MB (2007) Risedronate-induced Hepatitis. Am J Med 120:1–2
Laitinen K, Taube T (1999) Clodronate as a cause of aminotransferase elevation. Osteoporos Int 10:120–122
Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget’s disease of bone. J Bone Miner Metab 26:635–641
Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908
Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA (1996) Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 11:178–182
Dieterle F, Schlotterbeck G, Binder M, Ross A, Suter L, Senn H (2007) Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates. Chem Res Toxicol 20:1291–1299
Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033
Polyzos SA, Anastasilakis AD, Terpos E (2009) Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support Care Cancer 17:1329–1330
Polyzos SA, Kountouras J, Zavos C (2009) Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72:299–314
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Polyzos, S.A., Kountouras, J., Anastasilakis, A.D. et al. Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget’s disease of bone. Osteoporos Int 22, 363–367 (2011). https://doi.org/10.1007/s00198-010-1230-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-010-1230-5